[ad_1]
Nick Triggle, Rachel Schrea (BBC News)
Image courtesy of fake images
The UK Pharmaceutical and Medical Products Regulatory Agency (MHRA) said the recommendation was for people who had had an allergic reaction to a drug, food or vaccine.
Two British Civil Health Services (NHS) employees who received the vaccine on day 8 had an allergic reaction to the vaccine developed by Pfizer and Biontech.
Shortly after receiving the inoculation, they had an allergic reaction, but both were subsequently treated and are now stable.
They both had symptoms such as a rash, shortness of breath, and an anaphylactic reaction that tended to be accompanied by a drop in blood pressure. It is different from anaphylactic, which can be fatal.
All NHS employees have had severe allergic reactions in the past and have taken adrenaline injections to relieve allergic reactions.
Steven Pawis, NHS England medical director, said the two were on their way.
Pawis said that allergic reactions are “acquired with new vaccines” and that refraining from vaccinating people who have had similar symptoms is a precautionary measure.
Dr. June Rain, MHRA Director, said it was natural to take these steps now, as “this has happened.”
An allergic reaction like this is rare, but it can also occur with other vaccines, such as the annual flu shot.
Thousands of people were vaccinated in hospitals on day 8, when vaccination with the new virus began in the UK.
“We soon learned that the two were having an allergic reaction and regulators responded with preventive recommendations,” said Peter Openshaw, an immunology expert at Imperial College London. This shows that the surveillance system is working well. “
“Ready” for the deployment of the vaccine in the community
The NHS plans to extend its vaccination plan to general practitioner (GP) clinics starting next week.
First, the vaccine will be delivered to about 200 GP clinics and the inoculation will be available from the 15th day. Those over 80 will be the first to be vaccinated.
Once the vaccine is distributed to about 200 locations, the vaccination plan will expand to more than 1,000 clinics. Designated facilities will also be installed in each area.
This will allow most patients to get vaccinated at a different primary care facility than they usually do.
Similar adjustments are being made in other parts of the UK.
Dr Richard Votry, chairman of the British Medical Association (BMA) Committee for General Practitioners, said the GP was “ready.”
“We have a lot of experience in delivering vaccines. We will be able to serve millions of people a week. It depends on the supply of vaccines. It depends on how quickly we can get them.” In g “
Providing vaccines to 7.7 billion people around the world … 5 challenges New coronavirus
Oxford-size vaccine, “effective for the elderly”
In these circumstances, one of the key figures involved in vaccine development at the University of Oxford and AstraZeneca said there was no concern that the vaccine will not work for the elderly.
Sarah Gilbert said older subjects participated only in late clinical trials, and the results of the next clinical trial are likely to include information on the effectiveness of vaccines older than 55 years. Was.
But Gilbert said there was “no difference” in the immune response seen in young adults and people older than 70 in early clinical trials, showing that authorities can support the approval of vaccines for the elderly. Set.
MHRA is currently considering the use of vaccines with the University of Oxford and AstraZeneca.
This vaccine does not need to be stored at very low temperatures and is easier to store and distribute than other vaccines. Therefore, it is indispensable for the rapid deployment of vaccines. There are currently more than 5 million doses of this vaccine in the UK.
According to data released by the UK on the 9th, 533 people died within 28 days of being diagnosed with the new COVID-19 viral infection. Additionally, the number of people newly diagnosed with COVID-19 was 16,578 and the cumulative number of infected people was 1,766,819.
Infection measures
